go back

Brexucabtagene Autoleucel (Tecartus) CAR-T Therapy

Arkansas rates for HCPCS Q2053

Brexucabtagene autoleucel, up to 200 million autologous anti-CD19 CAR positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Rates data updated July 2026.

Facilitymedian $588,844 · 10th–90th $588,844$616,5950%50%90th$588,844Professionalmedian $489,779 · 10th–90th $489,779$588,8440%50%90th$489,779$500.0K$1.0M$2.0M

Distribution of negotiated rates across all payers (price axis is log-scale). Facility and professional rates are different services and are charted separately. Need provider-level prices? Contact us.

Insurance Carrier
Aetna
Setting
Facility
Modifier
Global
Typical Low
$588,843.66
Median
$588,843.66
Typical High
$616,595.00
Aetna
Setting
Professional
Modifier
Global
Typical Low
$489,778.82
Median
$489,778.82
Typical High
$588,843.66
Cigna
Setting
Professional
Modifier
Global
Typical Low
$489,778.82
Median
$489,778.82
Typical High
$588,843.66
United
Setting
Facility
Modifier
Global
Typical Low
$489,778.82
Median
$489,778.82
Typical High
$489,778.82
United
Setting
Professional
Modifier
Global
Typical Low
$363,078.05
Median
$467,735.14
Typical High
$812,830.52